glp-1-ras A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure Comprehensive Overview of GLP-1 RAs

Glucagon-like peptide-1 agonists (GLP-1s) have been in the spotlight as demand has grown to support type 2 diabetes and weight loss

Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimers disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs use...

While synthetic GLP-1 receptor agonists (RAs) like semaglutide and tirzepatide dominate clinical use, plant-derived GLP-1 modulators present a promising alternative due to their natural origin, diverse mechanisms, and potential for reduced side effects

In recent years, new drugs for the treatment of type 2 diabetes (T2D) have been proposed, including glucagon-like peptide 1 (GLP-1) agonists or sodiumglucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors

Please note that because GSK is unable to control the quality of our products sold by unauthorized sellers, the Guarantee is not available for products purchased from unauthorized sellers due to potential quality issues outside GSKs control

The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence